# Cortagen

> A Khavinson short peptide bioregulator (Ala-Glu-Asp-Pro) studied for cerebral-cortex and peripheral-nerve regeneration.

- Also known as: Ala-Glu-Asp-Pro, AEDP
- Class: Bioregulators
- FDA approved: No
- Canonical page: https://americanpeptide.com/catalog/cortagen

## Overview

Cortagen is one of the Khavinson short-peptide bioregulators — a synthetic tetrapeptide, Ala-Glu-Asp-Pro, developed in Russia and associated with the cerebral cortex and nervous tissue. Like the other bioregulators in this family, it is proposed to act as a tissue-specific, gene-regulatory signal, and it has been studied in Russian research for peripheral-nerve repair and CNS function. It is a research peptide, and its evidence base is largely from one research school and is not FDA-approved.

Cortagen belongs to the family of short peptide bioregulators developed by Khavinson and colleagues, each linked to a particular tissue — Cortagen to the cerebral cortex and nervous system. The governing idea is that very short peptides act as regulatory signals that normalize gene expression and function in their target tissue, and this catalog profiles several members (Cartalax, Pinealon, Cerluten, and others) on the same premise.

Research on Cortagen, mainly from Russian groups, has examined peripheral-nerve regeneration and cortical function. As with the family generally, independent replication is limited and the mechanism remains a hypothesis rather than an established pathway. It is a research compound and is not FDA-approved; this page is a research and educational reference.

## Mechanism

Proposed tissue-specific gene-regulatory activity (the Khavinson bioregulator hypothesis): short peptides binding DNA/chromatin to modulate expression in cortical and neural tissue. Mechanism is hypothesized more than proven in independent work.

## Sequence

```
AEDP
```

## Research areas

Studied in: Peripheral-nerve regeneration, Cerebral-cortex function, Peptide bioregulator research.

Guides on this site:

- [Peptide Bioregulators](https://americanpeptide.com/research-areas/bioregulators): Short, tissue-specific peptides proposed to regulate gene expression — the Khavinson series.

## Key research

- Cortex bioregulator — a Khavinson tetrapeptide (Ala-Glu-Asp-Pro) associated with the cerebral cortex and nervous tissue.
- Nerve-regeneration research — studied in peripheral-nerve-repair models.
- Gene-regulatory hypothesis — proposed to act as a tissue-specific regulator, like the rest of the bioregulator family.
- Limited independent evidence — mainly single-school research; not FDA-approved.

## Storage, handling & synthesis

**Storage.** Store lyophilized, frozen, and protected from light; refrigerate reconstituted peptide for short-term use. A tetrapeptide is physically simple but still degrades in solution over time.

**Handling.** Reconstitute gently. Because a 4-mer is trivial to produce under any label, the meaningful check is identity — mass spectrometry confirming the exact Ala-Glu-Asp-Pro sequence.

**Synthesis.** A linear tetrapeptide (Ala-Glu-Asp-Pro) — trivial to synthesize by solid-phase methods. Making it is easy; the real question is identity, because a 4-mer is cheap to produce under any label. A certificate should show mass spectrometry and HPLC assay confirming the exact sequence and purity.

## FAQs

### What is Cortagen?

A Khavinson short-peptide bioregulator (Ala-Glu-Asp-Pro) associated with the cerebral cortex and nervous tissue, studied for nerve regeneration and cortical function.

### How is it thought to work?

Through the bioregulator hypothesis — short peptides acting as tissue-specific, gene-regulatory signals. The mechanism is hypothesized more than independently proven.

### How strong is the evidence?

Limited and largely from one research tradition, with little independent replication. Treat it as an early research compound.

### Is it approved?

No — it is a research peptide, not FDA-approved. This page is a research and educational reference.

## Latest research

Recent trials and publications mentioning Cortagen, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily).

### Recent trials

- [Effects of Peptamen 1.6 in Malnourished Patients (or at Risk) With Pancreatic Neoplasia Undergoing Cephalic Pancreaticoduodenectomy (CPD): A Mechanistic Study](https://clinicaltrials.gov/study/NCT06852014) — RECRUITING · NA · NCT06852014

---

Source: AmericanPeptide.com — https://americanpeptide.com/catalog/cortagen
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.